Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
[lymphangioleiomyomatosis]
Lymphangioleiomyomatosis
(
LAM
)
is
a
rare
cystic
lung
disease
characterized
by
proliferation
of
smooth
muscle
like
cells
(
LAM
cells
)
that
have
mutations
in
the
tuberous
sclerosis
gene
(
TSC
2
)
,
leading
to
the
activation
of
the
mammalian
target
of
rapamycin
(
mTOR
)
.
Rapamycin
,
an
inhibitor
of
the
mTOR
pathway
,
has
been
shown
in
a
landmark
clinical
trial
to
halt
the
decline
in
lung
function
,
as
long
as
it
is
used
continuously
.
Women
with
severe
pulmonary
LAM
still
progress
to
require
lung
transplantation
.
The
use
of
inhibitors
of
the
mTOR
pathway
immediately
after
transplant
has
been
linked
to
bronchial
anastomotic
dehiscence
,
a
potentially
fatal
complication
of
lung
transplantation
.
Currently
,
it
is
recommended
that
women
with
LAM
stop
taking
rapamycin
once
listed
for
lung
transplant
,
which
could
potentially
lead
to
faster
lung
function
decline
while
awaiting
organ
transplantation
.
Here
we
review
the
existing
evidence
and
discuss
potential
recommendations
for
the
management
of
the
inhibitors
of
the
mTOR
pathway
while
awaiting
lung
transplantation
.
Diseases
Validation
Diseases presenting
"which could potentially lead to faster lung function decline while awaiting organ transplantation"
symptom
lymphangioleiomyomatosis
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom